This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
2 Instruments Stocks to Watch From a Prospering Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like MTD and BRKR are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.
MTDNegative Net Change BRKRNegative Net Change
biotechnology medical-devices tech-stocks
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
JAZZNegative Net Change AXSMPositive Net Change ANIXNo Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
After Golden Cross, Skillsoft Corp. (SKIL)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SKILNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
First Bancorp (FBNC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FBNCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
by Zacks Equity Research
Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
REGNNegative Net Change ALNYPositive Net Change NVSNegative Net Change RHHBYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?
by Ekta Bagri
While Gilead (GILD) has been under pressure year to date due to pipeline setbacks, holding on to this biotech giant should be prudent at current levels.
GSKNegative Net Change GILDPositive Net Change MRUSPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
by Zacks Equity Research
Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.
REGNNegative Net Change RAREPositive Net Change ANIXNo Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
by Nalak Das
Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.
ILMNNegative Net Change GMABNegative Net Change
biotechnology
Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback
by Ekta Bagri
Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.
GSKNegative Net Change BIIBNegative Net Change BMYPositive Net Change VTVTNegative Net Change
biotechnology biotechs pharmaceuticals
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
by Zacks Equity Research
Apellis (APLS) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
APLSNegative Net Change ANIXNo Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy AngioDynamics (ANGO) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ANGONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Bank First Corporation (BFC) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BFCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy United Community Banks (UCBI) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SouthState (SSB) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SSBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
by Zacks Equity Research
TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.
JNJNegative Net Change NVONegative Net Change TEVANegative Net Change ABBVNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
by Zacks Equity Research
Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
by Ekta Bagri
While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.
VRTXPositive Net Change PRMENegative Net Change CRSPNegative Net Change
biotechnology biotechs earnings-preview gene-therapy pharmaceuticals
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.
PCRXPositive Net Change ANIPNegative Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the second quarter of 2024 in both the United States and International segments.
BMRNNegative Net Change ZTSNegative Net Change DNLINegative Net Change APLSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Plumas Bancorp (PLBC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PLBCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
by Ekta Bagri
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
REGNNegative Net Change GSKNegative Net Change BIIBNegative Net Change VRTXPositive Net Change MRNANegative Net Change
biotechnology earnings pharmaceuticals
Kimco Realty (KIM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
KIMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy First United Corporation (FUNC) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FUNCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
First Community (FCCO)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FCCONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its second-quarter earnings release, given the absence of a marketed product.
BMRNNegative Net Change DNLINegative Net Change APLSNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals